How Avera's Hematology and Transplant Team Are Innovating to Save Lives  Avera Health

Excerpt from:
How Avera's Hematology and Transplant Team Are Innovating to Save Lives - Avera Health

First Patient Begins Newly Approved Sickle Cell Gene Therapy  The New York Times

See more here:
First Patient Begins Newly Approved Sickle Cell Gene Therapy - The New York Times

Study uncovers the secret of long-lived stem cells  Phys.org

Read the original:
Study uncovers the secret of long-lived stem cells - Phys.org

Black 12-Year-Old First Person To Get Sickle Cell Therapy  NewsOne

See the original post here:
Black 12-Year-Old First Person To Get Sickle Cell Therapy - NewsOne

New Jersey mother meets bone marrow donor who saved her life  PIX11 New York News

Visit link:
New Jersey mother meets bone marrow donor who saved her life - PIX11 New York News

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma  OncLive

More:
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma - OncLive

Emirati baby's life saved thanks to bone marrow transplant from pregnant grandmother  The National

View original post here:
Emirati baby's life saved thanks to bone marrow transplant from pregnant grandmother - The National

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.

Read the rest here:
Shockwave Medical Reports First Quarter 2024 Financial Results

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced that it will effect a 1-for-18 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on Thursday, May 9, 2024, and the Company's common stock will open for trading on The Nasdaq Global Select Market on May 9, 2024 on a post-split basis, under the existing ticker symbol "TBIO" but with a new CUSIP number 192003200. The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Global Select Market.

See the article here:
Telesis Bio Announces Reverse Stock Split

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update.

Read the original here:
Sana Biotechnology to Present at May and June 2024 Investor Conferences

Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025

Read more:
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

Read the original post:
Aileron Therapeutics to Present at Two Upcoming Investor Conferences

IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress, which takes place June 5-8, 2024 in Milan, Italy. EASL is the largest professional body in Europe devoted to liver health. Dr. Richard Van Etten, Helio’s Chief Medical Advisor, will present data from the Company’s pivotal Clinical Trial Multi-analyte Blood Test (CLiMB) study on Saturday, June 8 at 3:15 PM CET.

Original post:
Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024

Strengthens balance sheet by reducing total debt by approximately 80% over the past year Strengthens balance sheet by reducing total debt by approximately 80% over the past year

Read the original post:
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity

- Two clinical stage product candidates in development for the treatment of melanoma -

See more here:
Immuneering Recognizes Melanoma Awareness Month

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

View post:
Day One Reports First Quarter 2024 Financial Results and Corporate Progress

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company’s Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company’s lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatment of newly diagnosed AML patients.

Read more from the original source:
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Filed Pursuant to Rule 433

Read the original:
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor

Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period

The rest is here:
T2 Biosystems Announces First Quarter 2024 Financial Results

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programming & Data Operations, Xiaopeng “Jeff” Cai, MS; (ii) its newly appointed Vice President, Head of Biostatistics, Zhongwen “Justin” Tang, Ph.D.; and (iii) eleven other newly hired employees. The awards were approved by the Compensation Committee of Ocular and were made as inducements material to each individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more:
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)